Pharmaceutical bio companies seeking to release generics for Otezla, a psoriasis treatment that has not been released in Korea, are expanding. In addition to the existing Daewoong Pharmaceutical and Dong-A ST, DongKoo Bio, Huons, and Chong Kun Dang succeeded in overcoming two out of three related patents. If they overcome the remaining usage patents, they will be eligible for early release of the Otezla generic. According to the pharmaceutical industry on the 27th, Chong Kun Dang recently received a decision to establish a claim in a passive judgment to confirm the scope of rights for Otezla's patent filed against Amgen.

Otezla is protected by a total of three patents. These are two formulation patents